The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. Yet the iShares NASDAQ Biotechnology Index (ETF) IBB ended the week marginally lower.

Can the sector bounce back? Stay tuned to the following catalytic biotech events in the coming week. 

Medical, Biotech, Health Care Conferences

  • The International Symposium on Pediatric Neuro-Oncology: June 30-July 3 in Denver, Colorado.
  • 34th Annual Meeting of the European Society of Human Reproduction and Embryology: July 1-4 in Barcelona, Spain.
  • U.K. Radiological and Radiation Oncology Congress 2018: July 2-4 in Liverpool, England. 
  • 11th FENS Forum of Neuroscience: July 7-11 in Berlin, Germany.

Clinical Trial Results

NewLink Genetics Corp NLNK is scheduled to release updated Phase 1 data for its indoximod in combination with chemotherapy and radiation to treat diffuse intrinsic pontine glioma at the ISPNO on July 1.

Zogenix, Inc. ZGNX will release Phase 3 data for its ZX008 that is being evaluated in Study 1504 for Dravet syndrome in late June or early July.

Pending Releases From The First Half Of 2018

Acorda Therapeutics Inc ACOR is due to release Phase 2 data for BTT1023 in primary sclerosing cholangitis.

Roche Holdings AG Basel ADR Common Stock RHHBY will release Phase 3 data for its Tecentriq in combo with chemotherapy using Carboplatin and Abraxane based on the Impower132 study. The combo is being tested for squamous non-small cell lung cancer.

Novartis AG (ADR) NVS is scheduled to release Phase 2 data for LJN452 to treat non-alcoholic steatohepatitis.

Apellis Pharmaceuticals Inc APLS is due to release Phase 2 monotherapy data for its subcutaneously administrated APL-2 for auto-immune hemolytic anemia.

Novo Nordisk A/S (ADR) NVO will present Phase 3 data for its semaglutide oral formulation for Type 2 diabetes. The company will also release Phase 3 data for its Somapacitan, which is being evaluated in the REAL 3 study for adult growth hormone deficiency.

Cara Therapeutics Inc CARA is scheduled to present Phase 1 top-line data for its chronic kidney disease-associated pruritus treatment candidate Korsuva.

Zynerba Pharmaceuticals Inc ZYNE is due to release Phase 1 data for its ZYN001, evaluated for Tourette syndrome.

Celsion Corporation CLSN is due to release Phase 1b data for its GEN-1 in ovarian cancer.

CTI BioPharma Corp CTIC is slated to release an interim analysis of Phase 2 data for Pacritinib in the treatment of myelofibrosis.

Aclaris Therapeutics Inc ACRS is scheduled to release Phase 2 top-line data for its ATI-502 AA-202 in a topical application that's being evaluated for alopecia areata.

Titan Pharmaceuticals, Inc. TTNP will release Phase 1/2 data from the first patient cohort for the Ropinirole implant in the treatment of Parkinson's disease.

Asterias Biotherapeutics Inc AST and BioTime, Inc. BTX are scheduled to release further readouts of Phase 1/2 data on their cervical spinal cord injury treatment option AST-OPCI, which was evaluated in a study dubbed SCiSTAR. 

Related Links:

Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility

Achieve Life Sciences Shares Rip Higher On Positive Data For Smoking Cessation Drug

Posted In: BiotechNewsPreviewsTop StoriesTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.